Biotech Values

[DewDiligence]

Re: VRTX

I think we agree more than you may realize. To wit:

>I am not impressed with the reporting on the HCV developments coming out of AASLD. It seems quite incompetent. If you relied only on those reports and didn't do some thorough dd, certainly you would dump your shares. But you can also take this as an opportunity to pick up some cheap shares.<

I agree 100% with the above. The problem with owning VRTX until now has been its outsized valuation, but this has now been corrected, IMO. Telaprevir remains the most likely new HCV drug to succeed and I’ve said this repeatedly (#msg-23085478). Regards, Dew